MOTS-c and Clopidogrel Interaction: What Patients and Prescribers Need to Know
At a glance
- Interaction data / no published study of the pair found
- MOTS-c status / not an FDA-approved drug or a component of one [1]
- Clopidogrel / antiplatelet prodrug activated mainly by CYP2C19 [4]
- Genotype effect / CYP2C19 intermediate and poor metabolizers get less platelet inhibition [4]
- MOTS-c treatment evidence / cells and mice; human studies measured naturally occurring MOTS-c, not administered MOTS-c [5][2][3]
- MOTS-c dosing / no approved dose and no human dosing study [1]
- Sport / WADA S4.4.1, prohibited at all times [6]
Is there a known interaction?
No interaction has been documented. The FDA's 2026 review searched PubMed, Embase, the Cochrane library and other databases and found no clinical study in which MOTS-c was given to a person; the 12 papers the nominator cited were not clinical studies [1]. The FDA's compounding-safety page says it has not identified human exposure data for MOTS-c by any route [7]. Missing data is not a finding of safety: removal of MOTS-c from the FDA's safety-risk category was not a finding that it is safe [7].
How clopidogrel is switched on
Clopidogrel is an antiplatelet prodrug, activated mainly by CYP2C19. The 2022 CPIC guideline states that CYP2C19 intermediate and poor metabolizers on clopidogrel have reduced platelet inhibition and a higher risk of major adverse cardiovascular and cerebrovascular events [4].
What is known about MOTS-c
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [5]. Its treatment pharmacology comes from cells and mice: in one mouse study, 0.5 mg/kg/day given intraperitoneally produced about 20% lower body weight after 8 weeks on a high-fat diet [1]. Rodent doses cannot be converted into human doses [1].
The human studies measured the body's own peptide. In a randomized study of 30 healthy adults, plasma MOTS-c showed only a trend to rise after endurance exercise and was not related to fitness [3]. Another study reported that exercise raises endogenous MOTS-c in muscle and blood; those participants were not given the peptide [2].
MOTS-c is not an FDA-approved drug and is not a component of one. FDA staff proposed that it not be added to the list of bulk substances that can be used in compounding; a July 23, 2026 advisory committee vote in its favor was non-binding advice [1][8].
What to watch for
The FDA's stated concern for injectable peptides is immunogenicity from aggregation and peptide-related impurities, and MOTS-c has no immunogenicity data [1]. The products nominated to the FDA were 5 mg and 10 mg subcutaneous injections; there is no approved dose [1].
Frequently asked questions
Is MOTS-c FDA approved?
What dose of MOTS-c has been used in people?
Does CYP2C19 genotype affect clopidogrel?
Is MOTS-c banned in sport?
References
Show all 8 referencesHide references
- U.S. Food and Drug Administration.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.